[Federal Register Volume 82, Number 197 (Friday, October 13, 2017)]
[Notices]
[Page 47755]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-22147]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government and are available for licensing in the U.S.

FOR FURTHER INFORMATION CONTACT: Licensing information and copies of 
the patent applications listed below may be obtained by emailing the 
indicated licensing contact at the National Heart, Lung, and Blood, 
Office of Technology Transfer and Development Office of Technology 
Transfer, 31 Center Drive Room 4A29, MSC2479, Bethesda, MD 20892-2479; 
telephone: 301-402-5579. A signed Confidential Disclosure Agreement may 
be required to receive copies of the patent applications.

SUPPLEMENTARY INFORMATION: This notice is in accordance with 35 U.S.C. 
209 and 37 CFR part 404 to achieve commercialization of results of 
federally-funded research and development. Foreign patent applications 
are filed on selected inventions to extend market coverage for 
companies and may also be available for licensing. A description of the 
technology follows.

Small Interfering RNA Inhibition of Cannabanoid-1 Receptor (CB1R) for 
Treating Type 2 Diabetes

    Description of Technology: The invention pertains to the use of 
glucan encapsulated non-immunostimulatory small interfering RNAs 
(siRNAs) to treat type-2 diabetes. Endocannabinoids (EC) are lipid 
signaling molecules that act on the same cannabinoid receptors that 
recognize and mediate the effects of endo- and phytocannabanoids. EC 
receptor CB1R activation is implicated in the development of obesity 
and its metabolic consequences, including insulin resistance and type 2 
diabetes. Beta-cell loss has been demonstrated in a Zucker diabetic 
fatty (ZDF) rat model of type-2 diabetes through CB1R-mediated 
activation of a macrophage-mediated inflammatory response. Conversely, 
rats treated with a peripheral CB1R antagonist restores normoglycemia 
and preserves beta-cell function. Similar results are seen following 
selective in vivo knockdown of macrophage CB1R by daily treatment of 
ZDF rats with the instant D-glucan-encapsulated CB1R Small interfering 
RNA (siRNA). Knock-down of CB1R with using glucan encapsulated siRNA 
may represent a new commecializable method of treating type-2 diabetes 
or preventing the progression of insulin resistance to overt diabetes.
    Potential Commercial Applications: Treatment of obesity, insulin 
resistance, and diabetes.
    Development Stage: In vivo data available.
    Inventors: George Kunos, Tony Jourdan (NIAAA), Michael Czech, 
Myriam Aouadi.
    Intellectual Property: HHS Reference No. E-103-2013/0, U.S. 
Provisional Patent Application 61/839,239 filed June 25, 2013, 
International Patent Application PCT/US2014/043924 filed June 24, 2014, 
European Patent Application 14818342.9 filed June 24, 2014 and U.S. 
Patent Application 14/900,951 filed June 24, 2014.
    Licensing Contact: Michael Shmilovich, Esq, CLP; 301-435-5019; 
[email protected].

    Dated: October 5, 2017.
Michael Shmilovich,
Senior Licensing and Patenting Manager, National Heart, Lung, and Blood 
Institute, Office of Technology Transfer and Development.
[FR Doc. 2017-22147 Filed 10-12-17; 8:45 am]
 BILLING CODE 4140-01-P